• Clinical Evidence

Evaluating the Implementation of the EndoTool Glycemic Control Software System

Setting: 553-bed not-for-profit health care network.

Objective

This retrospective randomized study compares glycemic control and related outcomes before and after implementation of a glucose management software system (EndoTool) in several intensive care and progressive care units as well as the emergency department, all of which previously used a standard paper protocol.

Setting

553-bed not-for-profit health care network.

Results

  • Number of hours on an intravenous insulin drip decreased 12.5% with EndoTool, from 23.9 to 20.9 hours.
  • Incidence of hypoglycemia <70 mg/dL decreased 80.6% with EndoTool, from 0.036 to 0.007 episodes per patient.
  • Incidence of hyperglycemia >180 mg/dL decreased 20.9% with EndoTool, from 0.358 to 0.283 episodes per patient.
  • Mean average time to target decreased 24% with EndoTool, from 3.67 to 2.78 hours.
  • Mean average blood glucose decreased 6.75 mg/dL with EndoTool, from 193.24 to 186.49 mg/dL.

Conclusions

Implementation of a glucose management software system (EndoTool) promotes a culture of safety and can be expected to reduce costs, as evidenced by a wide array of improvements, including number of hours on an intravenous insulin drip as well as incidence of hypoglycemia, incidence of hyperglycemia, time to target and time in range.

Objective

This retrospective randomized study compares glycemic control and related outcomes before and after implementation of a glucose management software system (EndoTool) in several intensive care and progressive care units as well as the emergency department, all of which previously used a standard paper protocol.

Setting

553-bed not-for-profit health care network.

Results
  • Number of hours on an intravenous insulin drip decreased 12.5% with EndoTool, from 23.9 to 20.9 hours.
  • Incidence of hypoglycemia <70 mg/dL decreased 80.6% with EndoTool, from 0.036 to 0.007 episodes per patient.
  • Incidence of hyperglycemia >180 mg/dL decreased 20.9% with EndoTool, from 0.358 to 0.283 episodes per patient.
  • Mean average time to target decreased 24% with EndoTool, from 3.67 to 2.78 hours.
  • Mean average blood glucose decreased 6.75 mg/dL with EndoTool, from 193.24 to 186.49 mg/dL.
Conclusions

Implementation of a glucose management software system (EndoTool) promotes a culture of safety and can be expected to reduce costs, as evidenced by a wide array of improvements, including number of hours on an intravenous insulin drip as well as incidence of hypoglycemia, incidence of hyperglycemia, time to target and time in range.

References

Authors

Samuel John; Kacie Lauren Waters; Khatija Jivani.

Source

Published in Diabetes Spectrum, Volume 31, Issue 1, p26-30.

Year

2018

Quick navigation
Objective
Setting
Results
Conclusions
References
Objective

This retrospective randomized study compares glycemic control and related outcomes before and after implementation of a glucose management software system (EndoTool) in several intensive care and progressive care units as well as the emergency department, all of which previously used a standard paper protocol.

Setting

553-bed not-for-profit health care network.

Results
  • Number of hours on an intravenous insulin drip decreased 12.5% with EndoTool, from 23.9 to 20.9 hours.
  • Incidence of hypoglycemia <70 mg/dL decreased 80.6% with EndoTool, from 0.036 to 0.007 episodes per patient.
  • Incidence of hyperglycemia >180 mg/dL decreased 20.9% with EndoTool, from 0.358 to 0.283 episodes per patient.
  • Mean average time to target decreased 24% with EndoTool, from 3.67 to 2.78 hours.
  • Mean average blood glucose decreased 6.75 mg/dL with EndoTool, from 193.24 to 186.49 mg/dL.
Conclusions

Implementation of a glucose management software system (EndoTool) promotes a culture of safety and can be expected to reduce costs, as evidenced by a wide array of improvements, including number of hours on an intravenous insulin drip as well as incidence of hypoglycemia, incidence of hyperglycemia, time to target and time in range.

References

Authors

Samuel John; Kacie Lauren Waters; Khatija Jivani.

Source

Published in Diabetes Spectrum, Volume 31, Issue 1, p26-30.

Year

2018

Short and Sweet Headlines are Best!

Related posts

Image
  • Clinical Evidence

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

The objective of this study was to evaluate the impact of renal insufficiency on hypoglycemia rates in patients treated for Diabetic Ketoacidosis (DKA) utilizing a computerized insulin dosing algorithm.
Image
  • Clinical Evidence

Achieving Optimal Glucose Control in Critical Care Units at Atrium Health

20 minute read

Achieving Optimal Glucose Control in Critical Care Units at Atrium Health

The objective of this study was to evaluate the impact of different blood glucose (BG) target ranges for IV insulin infusions on inpatient glucose metrics, specifically focusing on hypo and hyperglycemic events, duration of IV insulin therapy, and length of stay (LOS) in the hospital.
Image
  • Clinical Evidence

Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

To compare the effectiveness of EndoTool IV in reducing hospital LOS and hypoglycemia rates compared to standard insulin infusion protocols.
Get in Touch

Ready to get started?

Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.